Skip to main content
. 2017 Oct 7;4(4):ofx212. doi: 10.1093/ofid/ofx212

Table 1.

Baseline Characteristics of FLU002 Outpatient and FLU003 Inpatient Cohort Enrollments and Influenza Virus Type/Influenza A Virus Subtype

FLU002 (N = 3952) FLU003 (N = 1398)
A(H1N1)pdm09 A(H3N2) B A(H1N1)pdm09 A(H3N2) B
Characteristics n = 1290 n = 1857 n = 805 P Valuea n = 641 n = 532 n = 225 P Valuea
Age, median (25th, 75th), y 35 (27, 47) 39 (30, 51) 42
(34, 53)
<.0001 49
(36, 61)
67
(49, 77)
59
(45, 71)
<.0001
18–34, % 50.9 39.3 28.7 <.0001 22.4 13.4 12.0 <.0001
35–49, % 30.7 34.0 40.3 30.3 12.2 19.1
50–64, % 15.7 19.6 25.6 32.5 19.9 32.9
65+, % 2.6 7.0 5.5 14.8 54.5 36.0
Female, % 52.7 52.8 49.9 .36 53.2 51.9 52.4 .71
Raceb <.0001 .08
Asian, % 26.7 19.5 20.0 11.1 16.7 13.8
Black, % 4.6 3.3 3.4 7.3 9.0 7.6
White/other, % 68.7 77.1 76.6 81.6 74.2 78.7
BMI, median (25th, 75th), kg/m2 24.6 (21.8, 28.1) 24.8 (22.0, 28.1) 25.1 (22.5, 28.8) .03 26.2 (23.0, 30.6) 26.3 (22.7, 31.3) 26.0 (22.9, 30.5) .62
Smoker, % 19.3 17.9 21.4 .12 29.4 16.3 19.1 <.0001
Pregnant, % of women aged ≤45 y 3.3 3.7 3.5 .94 24.8 23.5 38.5 .16
Vaccination in past 12 mo, % 13.9 19.1 16.0 .0005 26.2 49.6 36.4 <.0001
Antiviral therapy, % 1.9 1.0 0.7 .03 79.9 78.0 70.7 .03
Time since symptom onset, d <.0001 <.0001
0–3 d 84.8 87.6 77.1 21.9 35.7 22.8
4–5 d 10.5 9.2 15.0 24.3 26.1 24.2
≥6 d 4.6 3.2 7.8 53.8 38.2 53.0
Comorbidities
Asthma/COPD, % 5.9 5.5 4.1 .19 30.3 38.9 28.4 .003
Diabetes, % 3.5 3.7 4.3 .58 12.8 23.9 16.4 <.0001
CVD/liver/renal disease, % 2.8 3.7 4.8 .05 21.5 38.9 34.7 <.0001
HIV/other immune dysfunction, % 10.1 11.5 16.0 .0002 14.0 11.3 16.9 .10
Any of above, % 19.5 21.2 25.7 .003 54.4 73.5 65.3 <.0001

Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease.

aBaseline characteristics for influenza types/subtypes were compared in each study using the 2 degrees of freedom chi-square test for categorical statistics and Kruskal-Wallis rank for continuous variables. For FLU 003, P values are with stratification by ward at enrollment.

bIn FLU002, Asian sites enrolled 20% of patients, Australia 1%, Europe 29%, South America 42%, and North America (USA) 9%. In FLU003, Asian sites enrolled 11% of patients, Australia 13%, Europe 44%, South America 9%, and North America (USA) 23%.